SEC Filings

ARK And Cathie Wood Report 5.22% Stake In 10x Genomics, 6,272,998 Shares, In 13G/A

The passive-ownership amendment lists an event date of September 30, with most voting power held solely by ARK.

Matteo Parrino Jonathan Ponciano

Matteo Parrino, Jonathan Ponciano

— 2 min read
Share
ARK And Cathie Wood Report 5.22% Stake In 10x Genomics, 6,272,998 Shares, In 13G/A

ARK Investment Management and Catherine D. Wood reported owning 6,272,998 Class A shares of 10x Genomics, or 5.22% of the class, in a Schedule 13G/A filed Wednesday. The filing, a passive ownership disclosure, lists September 30 as the date of the event that triggered it.

What the filing says

This is Amendment No. 4 to the disclosure. It covers 10x Genomics Class A Common Stock, par value $0.00001 per share. ARK is listed as an investment adviser, and Wood as a parent holding company or control person.

ARK reported sole voting power over 6,028,612 shares and shared voting power over 63,202. Wood reported no sole voting power and shared voting power over 6,091,814 shares. Both rows show the same 6,272,998 shares and 5.22% of the class.

The signature block certifies that the shares were bought and are held in the ordinary course of business, and not to change or influence control of the company.

Where the stake sits

10x Genomics shares closed at $76.10 on Wednesday and slipped about 0.26% to $75.90 in Wednesday after-hours trading, an early reading in lighter volume (market data). The company's market capitalization is $10.5 billion, according to market data.

ARK's genomics fund has leaned heavily on the stock this year. Yahoo Finance reported that it had climbed to nearly six times its year-end 2025 close and made up about 10% of ARKG as of Oct. 2.

Benzinga reported that ARKG sold roughly $2.6 million of the stock on Monday, part of a broader biotech rebalancing.

The filing's voting split is the detail to read: ARK holds sole voting power over 6,028,612 shares, while Wood's 6,091,814 are all shared.

Sources

Read more